SHR-4849

N/A

Report date: 2025/07/23 13:41:07

Base Information

Drug NameSHR-4849
Drug Alias NameSHR-4849SHR4849IDE849IDE-849
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Delta-like protein 3DNA topoisomerase inhibitors
TargetsDelta-like protein 3DNA topoisomerase
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Hengrui Pharmaceutical Group Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesIdeaya Biosciences IncShanghai Hengrui Pharmaceutical Co LtdSuzhou Suncadia Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A